GCLC and colorectal cancer: Next, a CRISPR-Ecas9-engineered GCLC knockout (KO) variant of the colorectal cancer-derived organoid Tor10 (GCLC 24.1, Figure S3c) was used and compared to control Tor10 organoids that only expressed Ecas9 [27].